γ-Glutamyl transferase: A marker of nonalcoholic fatty liver disease in patients with the metabolic syndrome

European Journal of Gastroenterology and Hepatology

Volumn 24, Issue 7, 2012, Pages 805-810

  Banderas, Diana Zaineff ^a   Escobedo, Jorge ^a,b   Gonzalez, Evangelina ^b   Liceaga, María Gabriela ^a   Ramírez, Jesus Cenobio ^b   Castro, María Guadalupe ^a  

^a Hospital Regional 1 de Octubre   (Mexico)

^b INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

Author keywords

glutamyltransferase; metabolic syndrome; nonalcoholic fatty liver disease; population based cross sectional study; risk factors

Indexed keywords

ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; INSULIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; BODY WEIGHT; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; DOPPLER ECHOGRAPHY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; INCIDENCE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID OXIDATION; LIPID STORAGE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MEXICO; NONALCOHOLIC FATTY LIVER; OBESITY; OXIDATIVE STRESS; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; REAL TIME ECHOGRAPHY; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL; WAIST HIP RATIO;

ADULT; AGED; ANTHROPOMETRY; BIOLOGICAL MARKERS; BODY MASS INDEX; CLINICAL ENZYME TESTS; FATTY LIVER; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HEALTH SURVEYS; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; RISK FACTORS; SEX FACTORS; TRIGLYCERIDES; ULTRASONOGRAPHY, DOPPLER, DUPLEX;

EID: 84862226142     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0b013e328354044a     Document Type: Article

References (27)

1. Edmison J, McCullough AJ. Pathogenesis of non-alcoholic steatohepatitis: human data. Clin Liver Dis 2007; 11:75-104.
2. Tsai CH, Li TC, Lin CC. Metabolic syndrome as a risk factor for nonalcoholic fatty liver disease. South Med J 2008; 101:900-905.
3. Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 2005; 143:722-728.
4. Ong JP, Younossi ZM. Epidemiology and natural history of NAFLD and NASH. Clin Liver Dis 2007; 11:1-16.
5. Angelico F, Del Ben M, Conti R, Francioso S, Feole K, Fiorello S, et al. Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2005; 90:1578-1582.
6. Musso G, Gambino R, Bo S, Uberti B, Biroli G, Pagano G, et al. Should nonalcoholic fatty liver disease be included in the definition of metabolic syndrome? A cross-sectional comparison with Adult Treatment Panel III criteria in nonobese nondiabetic subjects. Diabetes Care 2008; 31: 562-568.
7. Schindhelm RK, Diamant M, Dekker JM, Tushuizen ME, Teerlink T, Heine RJ. Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease. Diabetes Metab Res Rev 2006; 22:437-443.
8. Kashyap SR, Diab DL, Baker AR, Yerian L, Bajaj H, Gray-McGuire C, et al. Triglyceride levels and not adipokine concentrations are closely related to severity of nonalcoholic fatty liver disease in an obesity surgery cohort. Obesity 2009; 17:1696-1701.
9. Lee DS, Evans JS, Robins SJ,Wilson PW, Albano I, Fox CS, et al. Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk. The Framingham Heart Study. Arterioscler Thromb Vasc Biol 2007; 27:127-133.
10. André P, Balkau B, Vol S, Charles MA, Eschwége E. on behalf of the DESIR Study Group. g-Glutamyltransferase activity and development of the metabolic syndrome (International Diabetes Federation Definition) in middle-aged men and women. Data from the Epidemiological Study on the Insulin Resistance Syndrome (DESIR) cohort. Diabetes Care 2007; 30: 2355-2361.
11. Koikea T, Miyamotob M, Oshida Y. Alanine aminotransferase and g-glutamyltransferase as markers for elevated insulin resistanceassociated metabolic abnormalities in obese Japanese men younger than 30 years of age. Obes Res Clin Pract 2010; 4:e73-e79.
12. Namipieri M, Gonzales C, Baldi S, Posadas R,Williams K, Haffner SM, et al. Liver enzymes, the metabolic syndrome, and incident diabetes. Diabetes Care 2005; 28:1757-1762.
13. Escobedo J, Schargrodsky H, Champagne B, Silva H, Boissonet CP, Vinueza R, et al. Prevalence of the metabolic syndrome in Latin America and its association with sub-clinical carotid atherosclerosis. The CARMELA cross sectional study. Cardiovasc Diabetol 2009; 8:52.
14. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285:2486-2497.
15. Charatcharoenwitthaya P. Role of radiologic modalities in the management of non-alcoholic steatohepatitis. Clin Liver Dis 2007; 11: 1137-1154.
16. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of high blood pressure. The JNC7 Report. Hypertension 2003; 42:1206-1252.
17. Jeong SK, Kim YK, Park JW, Shin YJ, Kim DS. Impact of visceral fat on the metabolic syndrome and nonalcoholic fatty liver disease. J Korean Med Sci 2008; 23:789-795.
18. Cheung O, Kapoor A, Puri P, Sistrun S, Luketic VA, Sargeant CC, et al. The impact of fat distribution on the severity of nonalcoholic fatty liver disease and metabolic syndrome. Hepatology 2007; 46:1091-1100.
19. Diehl AM. Hepatic complications of obesity. Gastroenterol Clin North Am 2009; 39:57-68.
20. Speliotes EK, Massaro JM, Hoffmann U, Vasan RS, Meigs JB, Sahani DV, et al. Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: The Framingham Heart Study. Hepatology 2010; 51:1979-1987.
21. Liangpunsakul S, Chalasani N. Unexplained elevations in alanine aminotransferase in individuals with the metabolic syndrome: results from the third National Health and Nutrition Survey (NHANES III). Am J Med Sci 2005; 329:111-116.
22. Uslusoy HS, Nak SG, Gülten M, Biyikli Z. Non-alcoholic steatohepatitis with normal aminotransferase values. World J Gastroenterol 2009; 15:1863-1868.
23. Meisinger C, Döring A, Schneider A. Löwel H for the KORA Study Group. Serum g-glutamyltransferase is a predictor of incident coronary events inapparently healthy men from the general population. Atherosclerosis 2006; 189:297-302.
24. Fraser A, Harris R, Sattar N, Ebrahim S, Smith GD, Lawlor DA. Gammaglutamyltransferase is associated with incident vascular events independently of alcohol intake. Analysis of the British Women's Heart and Health Study and Meta-Analysis. Arterioscler Thromb Vasc Biol 2007; 27:2729-2735.
25. Mason JE, Starke RD, Van Kirk JE. Gamma-glutamyl transferase: a novel cardiovascular risk biomarker. Prev Cardiol 2010; 13:36-41.
26. Dominici S, Paolicchi A, Lorenzini E, Maellaro E, Comporti M, Pieri L, et al. g-glutamyltransferase-dependent prooxidant reactions: a factor in multiple processes. BioFactors 2003; 17:187-198.
27. London RM, George J. Pathogenesis of NASH: animal models. Clin Liver Dis 2007; 11:55-74.